Cenexi restoration, new product launches and capability additions energy Gland Pharma outlook

Gland Pharma has gained 19% on the bourses previously three buying and selling periods to hit a 52-week excessive after the corporate reported a powerful March quarter and full-year efficiency. Cenexi, its European subsidiary, has began to point out a gradual enchancment in profitability after breaking even two quarters in the past. Whereas it’s anticipated to report a low double-digit income progress for FY27 amid geopolitical uncertainties, Gland administration expects a stronger momentum in FY28 given the capability additions and new product strains.

The inventory’s price-to-earnings (P/E) a number of at 35.6 stays under the three and five-year common of 37-38 regardless of the present rally, suggesting that valuations stay cheap. Given the expansion visibility, the inventory is more likely to keep on traders’ radar.

Gland Pharma’s acquisition of Cenexi in April 2023 has strengthened its European presence, with the area’s income share rising to 22% in FY26 from 5% in FY23. The corporate is focusing on round 10% income progress to 200 million in FY27 from 182 million in FY26, indicating a moderation compared with the 25% progress in FY26. Nevertheless, a bigger a part of the growth is predicted to play out from FY28, which is probably going to enhance progress prospects.

After reporting loss on the working stage in FY26, Cenexi is predicted to ship mid-to-high single-digit working margin earlier than depreciation and amortisation (EBITDA margin) in FY27. It’s more likely to broaden additional to mid-teen ranges over the medium time period.

The contract growth and manufacturing (CDMO) enterprise, which accounts for practically half of total income on the consolidated stage, grew by 28% in FY26. The corporate is focusing extra on complicated and high-margin CDMO alternatives, together with oncology, complicated injectables, peptides and drug supply techniques. A key CDMO mission is predicted to be commercialised within the second half of FY28, with an annual income potential of $25-30 million. To cater to the rising demand, the corporate has outlined a capital expenditure of ₹2,000 crore over the following 5 years aimed toward increasing the CDMO capability. The drug maker’s income rose 14.5% year-on-year in FY26 to ₹6,430.7 crore. It has guided for a 15% progress within the medium time period, led by new launches, ramp-up in key merchandise, higher utilisation, and Cenexi’s turnaround.